|
KMID : 1137020240350010043
|
|
Journal of Gynecologic Oncology
2024 Volume.35 No. 1 p.43 ~ p.43
|
|
|
Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines
|
|
Lee Bang-Hyun
Chang Suk-Joon
Kwon Byung-Su
Son Joo-Hyuk
Lim Myong-Cheol
Kim Yun-Hwan
Lee Shin-Wha
Choi Chel-Hun
Eoh Kyung-Jin
Lee Jung-Yun
Suh Dong-Hoon
Kim Yong-Beom
|
|
|
Abstract
|
|
|
|
Since the latest practice guidelines for ovarian cancer were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2021, many studies have examined the efficacy and safety of various treatments for epithelial ovarian cancer (EOC). Therefore, the need to develop recommendations for EOC treatments has been raised. This study searched the literature using 4 key items and the Population, Intervention, Comparison, and Outcome: the efficacy and safety of poly-ADP ribose polymerase inhibitors in newly diagnosed advanced EOC; the efficacy and safety of intraperitoneal plus intravenous chemotherapy in optimally debulked advanced EOC; the efficacy and safety of secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer; and the efficacy and safety of the addition of bevacizumab to platinum-based chemotherapy in first platinum-sensitive recurrent EOC patients who received prior bevacizumab. The evidence for these recommendations, according to each key question, was evaluated using a systematic review and meta-analysis. The committee of ovarian cancer of the KSGO developed updated guidelines for treatments of EOC.
|
|
|
KEYWORD
|
|
|
Epithelial Ovarian Cancer, Survival, Poly (ADP-ribose) Polymerase Inhibitor, Intraperitoneal Chemotherapy, Cytoreductive Surgery, Bevacizumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|